Related Experiment Video
Updated: Jul 26, 2025

11:00
Targeted Training of Ultrasonic Vocalizations in Aged and Parkinsonian Rats
Published on: August 8, 2011
19.8K
Acquired Stuttering in Parkinson's Disease.
Eloïse A Gooch1,2, Kyla-Louise Horne2, Tracy R Melzer1,2,3
1Te Kura Mahi ā-Hirikapo, School of Psychology, Speech, and Hearing University of Canterbury Christchurch New Zealand.
Movement Disorders Clinical Practice
|June 19, 2023
Summary
Acquired neurogenic stuttering affects 21% of people with Parkinson's disease (PD). This condition is linked to cognitive and motor impairments, not just motor deficits.
Area of Science:
- Neurology
- Speech-Language Pathology
Background:
- Parkinson's disease (PD) often leads to communication difficulties.
- The occurrence of new-onset stuttering in PD patients is not well understood.
Purpose of the Study:
- To investigate the prevalence of acquired neurogenic stuttering in individuals with PD.
- To explore the relationship between stuttering, cognitive function, and motor performance in PD.
Main Methods:
- 100 PD patients and 25 controls provided speech samples (conversation, picture description, reading).
- Stuttered disfluencies (SD) were identified and quantified.
- Neuropsychological tests and motor assessments were administered.
Main Results:
- PD participants exhibited significantly more SD during conversation compared to controls (2.2% vs 1.2%).
- 21% of PD patients met the diagnostic criteria for stuttering.
- SD in PD correlated with disease duration, levodopa dosage, and poorer cognitive and motor scores.
Conclusions:
- Acquired neurogenic stuttering is prevalent in PD, affecting 1 in 5 individuals.
- Speech disfluency assessment should be integrated into standard PD care.
- The findings challenge purely motor-based explanations for stuttering in PD, highlighting cognitive and motor links.
Related Concept Videos
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223

